本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Immunovant, Inc.

24.26
+0.52002.19%
成交量:12.92萬
成交額:309.70萬
市值:42.52億
市盈率:-8.59
高:24.30
開:23.84
低:23.50
收:23.74
52周最高:29.49
52周最低:12.72
股本:1.75億
流通股本:6,698.10萬
量比:0.63
換手率:0.19%
股息:- -
股息率:- -
每股收益(TTM):-2.8237
每股收益(LYR):-2.7303
淨資產收益率:-95.93%
總資產收益率:-55.42%
市淨率:8.18
市盈率(LYR):-8.89

資料載入中...

公司資料

公司名字:
Immunovant, Inc.
交易所:
NASDAQ
成立時間:
2018
員工人數:
362
公司地址:
320 West 37th Street,6th Floor,New York,New York,United States
郵編:
10018
電話:
傳真:
- -
簡介:
Immunovant, Inc.於2018年12月6日在特拉華州註冊成立,是一家臨床階段生物製藥公司,專註於為自身免疫性疾病患者提供正常生活。

董事

名稱
職位
Eric Venker
Chief Executive Officer and Director
Frank M. Torti
Executive Chairperson of board
Andrew Fromkin
Director
Atul Pande
Director
Douglas Hughes
Director
Jacob Bauer
Director
Robert Susman
Director

股東

名稱
職位
Eric Venker
Chief Executive Officer and Director
Melanie Gloria
Chief Operating Officer
Tiago Girao
Chief Financial Officer
Christopher Van Tuyl
Chief Legal Officer and Corporate Secretary
Frank M. Torti
Executive Chairperson of board
Jay S. Stout
Chief Technology Officer
Michael Geffner
Chief Medical Officer